Cargando…

Interleukin-1 blockade overcomes erlotinib resistance in head and neck squamous cell carcinoma

Erlotinib has demonstrated poor clinical response rates for head and neck squamous cell carcinoma (HNSCC) to date and the majority of respondents acquire resistance to erlotinib relatively quickly. To elucidate novel pathways involved in erlotinib resistance, we compared the gene expression profiles...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stanam, Aditya, Gibson-Corley, Katherine N., Love-Homan, Laurie, Ihejirika, Nnamdi, Simons, Andrean L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342798/ https://www.ncbi.nlm.nih.gov/pubmed/27738319 http://dx.doi.org/10.18632/oncotarget.12590

Ejemplares similares

2-Deoxy-d-glucose Suppresses the In Vivo Antitumor Efficacy of Erlotinib in Head and Neck Squamous Cell Carcinoma Cells
por: Sobhakumari, Arya, et al.
Publicado: (2016)

Interleukin-1 alpha increases anti-tumor efficacy of cetuximab in head and neck squamous cell carcinoma
por: Espinosa-Cotton, Madelyn, et al.
Publicado: (2019)

Susceptibility of Human Head and Neck Cancer Cells to Combined Inhibition of Glutathione and Thioredoxin Metabolism
por: Sobhakumari, Arya, et al.
Publicado: (2012)

MEK blockade overcomes the limited activity of palbociclib in head and neck cancer
por: Fang, Zhenghuan, et al.
Publicado: (2020)

Effects of Cetuximab and Erlotinib on the behaviour of cancer stem cells in head and neck squamous cell carcinoma
por: Setúbal Destro Rodrigues, Maria Fernanda, et al.
Publicado: (2018)

Sustained complete response to erlotinib in squamous cell carcinoma of the head and neck: A case report
por: Thinn, Mie Mie, et al.
Publicado: (2019)

Biomarker driven treatment of head and neck squamous cell cancer
por: Eze, Nnamdi, et al.
Publicado: (2017)

EREG-driven oncogenesis of Head and Neck Squamous Cell Carcinoma exhibits higher sensitivity to Erlotinib therapy
por: Liu, Shuli, et al.
Publicado: (2020)

Impact of Nuclear Interleukin-1 Alpha and EGFR Expression on Recurrence and Survival Outcomes in Oral Squamous Cell Carcinomas
por: Rajan, Anand, et al.
Publicado: (2019)

Erlotinib sensitivity of MAPK1p.D321N mutation in head and neck squamous cell carcinoma
por: Ngan, Hoi-Lam, et al.
Publicado: (2020)

Overcoming Resistance to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinomas
por: dos Santos, Lucas V., et al.
Publicado: (2021)

MAP2K1 is a potential therapeutic target in erlotinib resistant head and neck squamous cell carcinoma
por: Jain, Ankit P., et al.
Publicado: (2019)

Interleukin-6 role in head and neck squamous cell carcinoma progression
por: Choudhary, Moaz M., et al.
Publicado: (2016)

Aurora Kinase Inhibition Overcomes Cetuximab Resistance in Squamous Cell Cancer of the Head and Neck
por: Hoellein, Alexander, et al.
Publicado: (2011)

Overcoming the Impact of Hypoxia in Driving Radiotherapy Resistance in Head and Neck Squamous Cell Carcinoma
por: Hill, Rhianna M., et al.
Publicado: (2022)

Single Arm, Phase II Study of Cisplatin, Docetaxel, and Erlotinib in Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomas
por: William, William N., et al.
Publicado: (2018)

Inhibition of STAT3 by Niclosamide Synergizes with Erlotinib against Head and Neck Cancer
por: Li, Rui, et al.
Publicado: (2013)

Combining Radiation and Immune Checkpoint Blockade in the Treatment of Head and Neck Squamous Cell Carcinoma
por: Manukian, Gregor, et al.
Publicado: (2019)

Tumor hypoxia is associated with resistance to PD-1 blockade in squamous cell carcinoma of the head and neck
por: Zandberg, Dan P, et al.
Publicado: (2021)

Clinical-genomic determinants of immune checkpoint blockade response in head and neck squamous cell carcinoma
por: Valero, Cristina, et al.
Publicado: (2023)

Prognostic Role of Combined EGFR and Tumor-Infiltrating Lymphocytes in Oral Squamous Cell Carcinoma
por: Wongpattaraworakul, Wattawan, et al.
Publicado: (2022)

Blockade of deubiquitinating enzyme PSMD14 overcomes chemoresistance in head and neck squamous cell carcinoma by antagonizing E2F1/Akt/SOX2-mediated stemness
por: Jing, Chao, et al.
Publicado: (2021)

MAPK1(E322K) mutation increases head and neck squamous cell carcinoma sensitivity to erlotinib through enhanced secretion of amphiregulin
por: Wen, Yihui, et al.
Publicado: (2016)

Characterization of the Immune Response to PD-1 Blockade during Chemoradiotherapy for Head and Neck Squamous Cell Carcinoma
por: Callejas-Valera, Juan L., et al.
Publicado: (2022)

Cancer stem cells in head and neck squamous cell carcinoma
por: Karamboulas, Christina, et al.
Publicado: (2013)

Combinations of PRI-724 Wnt/β-Catenin Pathway Inhibitor with Vismodegib, Erlotinib, or HS-173 Synergistically Inhibit Head and Neck Squamous Cancer Cells
por: Kleszcz, Robert, et al.
Publicado: (2023)

Suppression of c-MET overcomes erlotinib resistance in tongue cancer cells
por: Huang, Keqiang, et al.
Publicado: (2018)

Phase I study of intra-arterial interleukin-2 in squamous cell carcinoma of the head and neck.
por: Gore, M. E., et al.
Publicado: (1992)

Association Between Interleukin-6 and Head and Neck Squamous Cell Carcinoma: A Systematic Review
por: Uz, Uzdan, et al.
Publicado: (2021)

Aggressive Cutaneous Squamous Cell Carcinoma of the Head and Neck: A Review
por: Desai, Neha, et al.
Publicado: (2023)

Irradiated fibroblasts increase interleukin-6 expression and induce migration of head and neck squamous cell carcinoma
por: Suzuki, Shinsuke, et al.
Publicado: (2022)

MTHFD2 Blockade Enhances the Efficacy of β-Lapachone Chemotherapy With Ionizing Radiation in Head and Neck Squamous Cell Cancer
por: Shukla, Kirtikar, et al.
Publicado: (2020)

Combined effects of bevacizumab with erlotinib and irradiation: a preclinical study on a head and neck cancer orthotopic model
por: Bozec, A, et al.
Publicado: (2008)

Novel Erlotinib–Chalcone Hybrids Diminish Resistance in Head and Neck Cancer by Inducing Multiple Cell Death Mechanisms
por: Murányi, József, et al.
Publicado: (2023)

Inhibition of Glutathione and Thioredoxin Metabolism Enhances Sensitivity to Perifosine in Head and Neck Cancer Cells
por: Simons, Andrean L., et al.
Publicado: (2009)

Early [18]FDG PET/CT scan predicts tumor response in head and neck squamous cell cancer patients treated with erlotinib adjusted per smoking status
por: Porosnicu, Mercedes, et al.
Publicado: (2022)

Immunotherapy in head and neck squamous cell carcinoma and rare head and neck malignancies
por: Cavalieri, Stefano, et al.
Publicado: (2021)

Gemcitabine Overcomes Erlotinib Resistance in EGFR-Overexpressing Cancer Cells through Downregulation of Akt
por: Bartholomeusz, Chandra, et al.
Publicado: (2011)

Macromolecular osteolytic factor synthesised by squamous carcinoma cell lines from the head and neck in vitro is interleukin 1.
por: Meghji, S., et al.
Publicado: (1988)

The Role of Interleukin-33 in Head and Neck Squamous Cell Carcinoma Is Determined by Its Cellular Sources in the Tumor Microenvironment
por: Peng, Liang, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lbi86pvsch99m82u6drh4068cj